ReviewFrontiers in pharmacology2015
A pretargeting system for tumor PET imaging and radioimmunotherapy.
Review in Frontiers in pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Bispecific Antibodies: From Research to Clinical Application.Frontiers in immunology · 2021Pooled it
- Preclinical evaluation of a novel tetrazine probe within a pretargeted delivery system for theranostics in HER2-positive tumor-bearing mice models.Acta pharmaceutica Sinica. B · 2026Article
- Clinical research analysis of [European journal of nuclear medicine and molecular imaging · 2026Article
- Article
- Carrier systems of radiopharmaceuticals and the application in cancer therapy.Cell death discovery · 2024Review
- Pretargeting: A Path Forward for Radioimmunotherapy.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Review
- Radionuclide Imaging of Cytotoxic Immune Cell Responses to Anti-Cancer Immunotherapy.Biomedicines · 2022Review
- Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Article
- Promising clinical performance of pretargeted immuno-PET with anti-CEA bispecific antibody and gallium-68-labelled IMP-288 peptide for imaging colorectal cancer metastases: a pilot study.European journal of nuclear medicine and molecular imaging · 2021Article
- Article
- Radioimmunotherapy for solid tumors: spotlight on Glypican-1 as a radioimmunotherapy target.Therapeutic advances in medical oncology · 2021Article
- Identify. Quantify. Predict. Why Immunologists Should Widely Use Molecular Imaging for Coronavirus Disease 2019.Frontiers in immunology · 2021Review
- Targeted Alpha Therapy: Progress in Radionuclide Production, Radiochemistry, and Applications.Pharmaceutics · 2020Review
- Pretargeted radioimmunoimaging with a biotinylated D-DThe Journal of international medical research · 2020Article
- ImmunoPET: Concept, Design, and Applications.Chemical reviews · 2020Review
- Pretargeted delivery of PI3K/mTOR small-molecule inhibitor-loaded nanoparticles for treatment of non-Hodgkin's lymphoma.Science advances · 2020Article
- The Impact of Positron Range on PET Resolution, Evaluated with Phantoms and PHITS Monte Carlo Simulations for Conventional and Non-conventional Radionuclides.Molecular imaging and biology · 2020Article
- A pretargeted multimodal approach for image-guided resection in a xenograft model of colorectal cancer.EJNMMI research · 2019Article
- Targeting the Tetraspanins with Monoclonal Antibodies in Oncology: Focus on Tspan8/Co-029.Cancers · 2019Review
- PET Imaging of Receptor Tyrosine Kinases in Cancer.Molecular cancer therapeutics · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Labeled antibodies, as well as their fragments and antibody-derived recombinant constructs, have long been proposed as general vectors to target radionuclides to tumor lesions for imaging and therapy. They have indeed shown promise in both imaging and therapeutic applications, but they have not fulfilled the original expectations of achieving sufficient image contrast for tumor detection or sufficient radiation dose delivered to tumors for therapy. Pretargeting was originally developed for tumor immunoscintigraphy. It was assumed that directly-radiolabled antibodies could be replaced by an unlabeled immunoconjugate capable of binding both a tumor-specific antigen and a small molecular weight molecule. The small molecular weight molecule would carry the radioactive payload and would be injected after the bispecific immunoconjugate. It has been demonstrated that this approach does allow for both antibody-specific recognition and fast clearance of the radioactive molecule, thus resulting in improved tumor-to-normal tissue contrast ratios. It was subsequently shown that pretargeting also held promise for tumor therapy, translating improved tumor-to-normal tissue contrast ratios into more specific delivery of absorbed radiation doses. Many technical approaches have been proposed to implement pretargeting, and two have been extensively documented. One is based on the avidin-biotin system, and the other on bispecific antibodies binding a tumor-specific antigen and a hapten. Both have been studied in preclinical models, as well as in several clinical studies, and have shown improved targeting efficiency. This article reviews the historical and recent preclinical and clinical advances in the use of bispecific-antibody-based pretargeting for radioimmunodetection and radioimmunotherapy of cancer. The results of recent evaluation of pretargeting in PET imaging also are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.